Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) and Paratek Pharmaceuticals Inc. (NASDAQ:PRTK), both competing one another are Biotechnology companies. We will compare their risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Foamix Pharmaceuticals Ltd.	3.60M	60.04	74.16M	-2.00	0.00
Paratek Pharmaceuticals Inc.	17.12M	11.89	112.36M	-3.64	0.00

We can see in table 1 the earnings per share, top-line revenue and valuation of Foamix Pharmaceuticals Ltd. and Paratek Pharmaceuticals Inc.

Profitability

Table 2 demonstrates the net margins, return on equity and return on assets of Foamix Pharmaceuticals Ltd. and Paratek Pharmaceuticals Inc.

	Net Margins	Return on Equity	Return on Assets
Foamix Pharmaceuticals Ltd.	-2,060.00%	-121.5%	-102%
Paratek Pharmaceuticals Inc.	-656.31%	-132.5%	-44.6%

Risk and Volatility

Foamix Pharmaceuticals Ltd. has a beta of 1.67 and its 67.00% more volatile than S&P 500. Competitively, Paratek Pharmaceuticals Inc.’s 71.00% volatility makes it more volatile than S&P 500, because of the 1.71 beta.

Liquidity

The Current Ratio of Foamix Pharmaceuticals Ltd. is 12.4 while its Quick Ratio stands at 12.4. The Current Ratio of rival Paratek Pharmaceuticals Inc. is 11.4 and its Quick Ratio is has 11.4. Foamix Pharmaceuticals Ltd. is better equipped to clear short and long-term obligations than Paratek Pharmaceuticals Inc.

Analyst Recommendations

Ratings and Recommendations for Foamix Pharmaceuticals Ltd. and Paratek Pharmaceuticals Inc. can be find in next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Foamix Pharmaceuticals Ltd.	0	0	4	3.00
Paratek Pharmaceuticals Inc.	0	0	4	3.00

Foamix Pharmaceuticals Ltd.’s average target price is $17, while its potential upside is 328.21%. Competitively the average target price of Paratek Pharmaceuticals Inc. is $21.25, which is potential 238.38% upside. Based on the analysts belief we can conclude, Foamix Pharmaceuticals Ltd. is looking more favorable than Paratek Pharmaceuticals Inc.

Insider and Institutional Ownership

Foamix Pharmaceuticals Ltd. and Paratek Pharmaceuticals Inc. has shares held by institutional investors as follows: 64.8% and 77.7%. Foamix Pharmaceuticals Ltd.’s share held by insiders are 1.3%. On the other hand, insiders held about 3.1% of Paratek Pharmaceuticals Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Foamix Pharmaceuticals Ltd.	7.14%	3.59%	-6.72%	-34.67%	-36.97%	4.46%
Paratek Pharmaceuticals Inc.	-6.09%	0.67%	-8.98%	-32.44%	-46.95%	32.36%

For the past year Foamix Pharmaceuticals Ltd. has weaker performance than Paratek Pharmaceuticals Inc.

Summary

Foamix Pharmaceuticals Ltd. beats Paratek Pharmaceuticals Inc. on 6 of the 11 factors.

Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations primarily for the treatment of moderate-to-severe acne, moderate-to-severe papulo-pustular, rosacea, and other skin conditions in the United States, Germany, and France. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline, which has completed a dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by methicillin-resistant staphylococcus aureus. The company is also developing FMX103, a version of its minocycline foam FMX101, which is in Phase II clinical trial for the treatment of rosacea; and FDX104 that has completed Phase II clinical trial for the treatment of chemotherapy-induced rash. Foamix Pharmaceuticals Ltd. has development and license agreements with Bayer HealthCare AG; Sebela Pharmaceuticals Inc.; Mylan N.V.; and Actavis Laboratories. The company was founded in 2003 and is headquartered in Rehovot, Israel.

Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, a broad-spectrum, intravenous, and oral antibiotic, which is in Phase III clinical stage for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound that is in Phase III clinical trial for the treatment of acne and rosacea. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III studies for ABSSSI and CABP. It has collaborative research and license agreement with Allergan plc to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and license agreement with Shin Nippon Biomedical Laboratories Ltd. to develop TO-2070 for the treatment of acute migraine. The company also has a cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.